Between 1992 and 1999, 105 unrelated allogeneic bone marrow collections from 103 volunteer donors (65 males and 38 females; median age 33 years) were carried out in three northern Italian centers (Verona, Bolzano and Padova) affiliated with the Italian Bone Marrow Donor Registry (IBMDR). The average volume of BM collected was equivalent in both genders (1143.1 ml for males and 1054.2 ml for females; P = 0.1), although the average volume collected for unit of body weight and the average post-collection blood volume depletion was higher in females (respectively 17.1 ml/kg and 14.2% in females, 14.8 ml/kg and 12% in males; P = 0.01 and 0.03). There was no statistically significant difference between males and females in the total number of nucleated cells collected. We did not record any acute life-threatening event during or after the bone marrow collections. The most frequent complaint was pain at the collection site (77%) followed by the onset of fatigue (38%) and nausea and vomiting (25%); all of these were short-term problems. Hospitalization was short (average 20.2 h) and donors started their normal daily activities after an average of 5.4 days. We also monitored Hb, serum ferritin levels, WBC and platelet counts in the post-collection period (average follow-up 40.1 months). All donors signed a written informed consent for a further bone marrow collection, if needed. Our findings confirm the short-and long-term safety of allogeneic bone marrow collection in volunteer donors. Bone Marrow Transplantation (2001) 28, 369-374.
Until the late 1970s, only allogeneic BM transplants from fully HLA matched sibling donors were performed.
1,2 However more than 60% of patients suffering from hematologic malignancies did not have a sibling match and early reports of successful allogeneic BM transplants from unrelated donors [3] [4] [5] [6] pressed transfusion centers, in the early 1980s, for HLA typing of their blood donors. Starting in 1986 BM donor registries were created in both the USA and Europe. 7, 8 Since then, BM donor registries have been created world-wide, enrolling millions of volunteer donors with thousands of BM collected; [9] [10] [11] [12] [13] there are currently 46 registries located in 36 countries, counting for 6.5 million potential BM donors (last up-date June 2000). The Italian Bone Marrow Donor Registry (IBMDR) was created in 1989 and there are currently 270 000 enrolled donors with 700 BM collections already performed (last up-date October 2000).
Allogeneic BM transplantation has mostly been regarded from the recipient's point of view, by analyzing the impact of this therapeutic procedure on the disease history; there are very few data considering the BM donor's safety. [14] [15] [16] [17] [18] In our report, we exclusively focus on the volunteer donor: we report 105 BM collections from 103 volunteer donors, recorded in the Regional Registry of Veneto and TrentinoAlto Adige from 1992 to 1999. We analyzed social and personal data of our donors, bone marrow collection-related data (nature of anesthesia, nucleated cell number and collection volume, autologous blood program efficacy) and effect that the BM collection had on the donors in the short term (hospitalization and recovery time, adverse effects) and in the long-term (impact on hemopoiesis by evaluation of a number of hematochemistry parameters).
Materials and methods
From January 1992 to December 1999, 105 BM collections were carried out in three collection centers (Verona, Bolzano and Padova) from 103 volunteer donors of the Regional Registry of Veneto and Trentino-Alto Adige (co-ordinator center: Verona), which is part of the IBMDR. The donors had been enrolled in 13 donor centers of the Regional Registry. Since two donors underwent two BM collections for the same patients, 105 BM collections were eventually carried out. The BM collections were performed in the following cities: Bolzano eight, Padova 12, Verona 85.
Donor selection
The suitability criteria for acceptance in the IBMDR as a potential BM donor were the following: (1) Entry age between 18 and 35 years. BM donors are kept on the registry and are suitable for BM collection until 55 years of age; (2) Free from chronic physical and mental diseases; (3) Satisfying the Italian law requirements to be considered suitable for blood donation; (4) Free from behavioural risk for blood-borne disease; (5) If female, must not be pregnant.
During the enrolment visit, a physician informed the potential donor about the indication for and outcome of allogeneic BM transplantation, the tests to be performed on the donor, the BM collection procedure, the kind of anesthesia and its risks. The donor was informed that donation had to be voluntary, anonymous and unpaid, that the BM collection required 24 to 48 h of hospitalization and a recovery period of about 5 days. The enrolled donor signed a consent form and underwent blood sampling for blood typing and HLA-A and -B serology typing (first level). Personal and laboratory data were mailed to the IBMDR national co-ordinator at the Galliera Hospital in Genova (Italy). Data were then put into the Italian data bank which is linked to other international registries. When requested from the national co-ordinator, donors were called to undergo three further tests: the second level included the low resolution PCR for HLA DR and DQ typing; the third and fourth level included the high resolution PCR for HLA DRB, DRQ and DP typing and infectious diseases markers (hepatitis B surface antigen, antibodies to hepatitis C virus, HIV and CMV).
If a donor was finally shown to be compatible with the patient waiting for the transplant, 3 weeks before the scheduled BM collection the donor was requested to go to the donor center to undergo a physical examination, hematochemistry (cell blood count, liver and renal functional tests), virology screening (hepatitis B surface antigen, hepatitis B core antigen, antibodies to hepatitis C virus, HIV, CMV HSV, VZV and EBV), chest radiography and electrocardiogram. About 10 days prior to the scheduled BM collection, a final meeting had to be arranged with the donor, the hematologist of the collection center, the physician of the coordinator center and the anesthetist. In this meeting the donor's final suitability and medical clearance had to be released, and information was further given, including the collection procedure, the kind of anesthesia and its related risk, the hospital stay period and the need of a recovery period when the donor could not attend his/her normal daily activities. Donors were informed about the opportunity to undergo an autologous blood donation and the possibility of receiving iron supplementation after the collection to speed up the hemoglobin return to baseline values. Donors were informed that after giving their final consent, the patient would be started on conditioning chemo-radiotherapy for BMT and without the donor BM collection the procedure would be fatal. Donors were also informed about the possibility of a second BM collection and transplant if the first transplant failed; donors could make this decision after the BM collection.
After having obtained the final consent, donors were started on the autologous blood donation program (one or two units, each of 350 or 450 ml). The first unit of whole blood was collected on the same day as the final meeting, while a second unit of blood, if needed, was to be drawn 72 h prior to the BM collection. The average blood volume depletion after BM collection, expressed as percentage of the average total blood volume, was calculated by subtracting, from the assumed blood volume of the patient, the difference between the volume of the blood collected in the BM collection and the blood transfused with the autologous transfusion. The assumed blood volume was calculated by considering it as 7% of total body weight.
Marrow collection
Donors were admitted to the collection center on the evening before the scheduled BM collection day. Donors were assigned a progressive identification number which was used to identify the collected marrow. The next morning, donors underwent general or epidural anesthesia and the marrow was collected from both posterior-superior iliac spines and if needed, from the sternum too. Donors received i.v. heparin at the time of collection (100 U/kg). Marrow was collected by multiple aspirations, each of 5 ml, done at three or four different levels through a single skin puncture, in order to decrease the amount of blood contamination. 19 Marrow was then filtered in the operating room using blood transfusion filters (Emoplus, Plasti Medical, Italy). Marrow was placed in sterile bags each containing a 10 ml solution of 10% heparin. A cell blood count was performed at the mid and end point of the procedure, to evaluate the total nucleated cell number (TNC). Marrow was then handed to a courier and transported to the transplant center. Based on the end point cell blood count, the physician decided whether or not to transfuse the stored autologous blood and start the donor on i.v. iron supplementation therapy. Prior to discharge donors had to fill in a questionnaire on their physical and mental status and at this time donors were questioned about their availability, if needed, to be called for a possible further BM collection for the same patient. A blood count was performed prior to discharge and the need for oral iron supplementation therapy was then decided.
Donor follow-up
Donors were surveyed by donor center personnel by telephone 1 week after discharge and questioned about their health status; those donors with complaints were either invited to go to their donor center or they were called until resolution of the reported problem. The follow-up protocol included blood tests (blood cell count, serum ferritin) at 1, 3 and 6 months after the BM collection. A yearly check was scheduled afterwards. During the check donors also underwent clinical examination; the length of the oral iron supplementation therapy was decided based on the blood count and serum ferritin levels. One year after the BM collection, blood donors could again donate blood.
Statistical analysis
Statistical analysis was carried out by paired t test. P value equal or less than 0.05 were considered statistically significant.
Results
The social and personal data of 103 donors are reported in Table 1 . Donors were subdivided by kind of daily activity (physical or intellectual tasks) to analyze a possible correlation between working activity and recovery. The donors with heavy daily tasks (workers, farmers, policemen) were 53 out of 103 (51.4%; 37 males and 16 females); donors unemployed or with mild/moderate daily tasks (students, employees, professionals) were 50 out of 103 (48.6%; 38 males and 22 females). Marrow collection data (total volume of marrow collected and volume collected per unit of donor weight, total nucleated cells requested, collected and ratio) are reported in Table 2 . Most donors opted for total anesthesia (102/105; Table 3 shows the complaints related to BM donation reported during the hospital stay and during the follow-up period. Nausea and/or vomiting were reported from 25% of donors; vomiting was treated with i.v. anti-emetic drugs (9/105; 8.6%). These latter symptoms were considered short-term complaints since they were only reported during the hospital stay. Eighty-one donors (77.1%) complained about pain at the collection site; this was mild to moderate, Table 3 Complaints reported during the hospitalisation and during the follow-up period for an average period of 2.6 months (range 1-7 months) and 1.5 months (range 1-4 months), respectively. As to the prescribed convalescence period, the 54 male donors were given an average of 4.6 days off work (range 0-14 days), while female donors need an average of 6.7 days of rest (range 0-20 days). Table 4 correlates, according to sex, the recovery period (more or less than 4 days) with a few variable conditions like blood donor status, nature of work, difference between the volume of BM collected and volume of the autologous Table 4 Correlation, according to sex, with recovery period, blood donor status, kind of work, average blood volume depletion, and difference between marrow collected and autologous blood transfused blood transfused and blood volume depletion. In male donors, a higher number of days off work was correlated with previous blood donor status and the kind of job, while in female donors it correlated with the average blood volume depletion and kind of job. Figures 1 and 2 show the values of a few parameters (hemoglobin and serum ferritin) that we checked before the BM collection (time 0) and during follow-up at 1, 3, 6, 12, 24 and 48 months, with an average follow-up of 40.1 months (range 3-96 months). The drop in hemoglobin levels at the time of discharge compared to the pre-collection baseline values was equivalent in both genders: the average hemoglobin level dropped from 15.2 g/dl (range 13.2-16.9 g/dl) to 13.4 g/dl (range 11.4-15.1 g/dl) in males and from 12.8 g/dl (range 11.3-14.4 g/dl) to 11.1 g/dl (range 9.6-12.7 g/dl) in females (normal range 13-18 g/dl for males and 12-16 g/dl for females). Hemoglobin levels reverted to the pre-collection baseline levels after 3 months in males and after 1 month in females. Serum ferritin levels reverted to the pre-collection baseline levels (52.4 ± 29.9 g/l in males and 13.3 ± 12.8 g/l in females; normal range 15-280 g/l and 5-100 g/l, respectively) after 6 months in males and after 1 month in females. White blood cell (normal range 4-11 × 10 9 /l) and platelet (normal range 150-400 × 10 9 /l) counts before and after the BM collection and at various time points during the follow-up did not show any statistically significant difference in either males or females (Table 5 ). After the BM collection all donors agreed and gave written consent for a further collection for the same patient, if needed. Two out of 103 donors (1.9%) did undergo a second BM collection respectively at 3 and 6 months after the first one. Recovery in these latter two donors was comparable to other data. During the yearly follow-up, no donor reported any complaint related to the BM collection.
Complaints

Discussion
Allogeneic BM transplantation has been widely analyzed from a recipient's point of view, 2 mainly considering the impact that the transplant procedure has on the course of the disease. A few studies have analyzed the impact of the BM donation on the donor's safety [14] [15] [16] [17] [18] and even fewer studies report on donor follow-up. [14] [15] [16] In this study, we report 105 consecutive BM collections from 103 volunteer donors carried out over an 8-year period at three donor centers in northern Italy (Verona, Bolzano and Padova), analyzing the donors personal data prior to the BM collection, the BM procedure and the side effects of the BM donation. We also carried out a clinical and laboratory follow-up over a 40-month period. Most donors were already blood donors and all working categories were represented. A heavy job Table 5 Pre-and post-collection white blood cell and platelet values was related to a longer post-collection absence from working activities compared to those donors with daily mild to moderate working activity; however the average hospitalization (20.2 h) and the average convalescence length (5.4 days) were shorter than reported in the literature. 15 As to the collected marrows, we always succeeded in obtaining the TNC quantities that the transplant centers requested (TNC collected/TNC requested: 0.99%) with similar values in both sexes. Moreover, while the average volume of marrow collected and the average difference between volume of marrow collected and volume transfused with autologous blood was equivalent in both sexes, blood volume depletion was clearly higher in women (14.2% vs 12%, P = 0.03). This finding is explained by the different weight (76.8 kg in males (range 60-112 kg) and 62.4 kg (range 50-98 kg) in females, P Ͻ 0.001) and consequently different blood volume (5400 ml in males (range 4200-7840 ml) and 4380 ml in females (range 3500-6860 ml)).
As reported in the literature, 15 our results show that BM collection can be considered to be a safe procedure. Specifically, we only reported acute complaints that could be considered of minor importance but we did not report any acute life-threatening events. Pain at the collection site was the most frequent complaint, being reported by 77% of donors; in the majority of cases the pain was short lasting (average 5 days) and of mild to moderate intensity and only a minority of donors (7%) needed analgesia. Fatigue was the second most frequent complaint, being reported by 38% of donors; the fact that females complained more frequently about fatigue (65.8% vs 23.1%, P Ͻ 0.001) was probably due to their higher average blood volume depletion (14.2% vs 12%, P = 0.03). Nausea was also a common complaint, being reported by 25% of donors; however, vomiting was present along with nausea in only 8.6% of donors. The frequency of reported complaints was overall lower than reported in the literature. 15 Among the less frequent complications, we report the late onset of a depressive syndrome (1 month after the BM donation) in two female donors, one of whom had previously been treated for a similar syndrome. Although we can not draw any conclusions from this latter finding, if these data were confirmed in further studies, they would suggest the need for a psychological, as well as laboratory, follow-up of donors. We emphasize the effectiveness of the autologous blood donation, which allowed all donors to avoid the risks linked with allogeneic blood transfusions.
As to the laboratory values during the follow-up period, we observed that the post-collection haemoglobin drop was equivalent in both sexes (1.8 g/dl in males and 1.7 g/dl in females) although return to pre-collection baseline values was faster in females (1 month in females, 3 months in males). This finding can be explained by the fact that 80% of female and only 35% of male donors underwent iron supplementation therapy. These data were confirmed by the overlapping trend of the serum ferritin level in the postcollection period; while it took up to 6 months in males to return to pre-collection baseline levels, in females serum ferritin levels returned to normal values after the first month post-collection and then increased to higher than the precollection baseline values from 3 to 12 months. White blood cell and platelet counts did not show any statistically significant difference during the follow-up period.
We emphasize the fact that all donors were highly motivated and satisfied with the BM donation experience. All donors gave their consent for a second BM collection, if needed. Data reported in our study confirm that allogeneic BM collection can be considered a safe procedure for the donor in the short, as well as in the long term.
